12-Month Observation of Testosterone Replacement Effectiveness in a General Population of Men

References

• . Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–769
   PubMed Web of Science ®Google Scholar
• . Carruthers M. Time for international action on treating testosterone deficiency syndrome. Aging Male. 2009;12(1):21–28
   PubMed Web of Science ®Google Scholar
• . Hall SA, Araujo AB, Esche GR, . Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch Intern Med. 2008;168(10):1070–1076
   PubMedGoogle Scholar
• . Bhasin S, Cunningham GR, Hayes FJ, . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559
   PubMed Web of Science ®Google Scholar
• . Wylie K, Rees M, Hackett G, . Androgens, health and sexuality in women and men. Maturitas. 2010;67(3):275–289
   PubMed Web of Science ®Google Scholar
• . Wang C, Nieschlag E, Swerdloff R, . Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159(5):507–514
   PubMed Web of Science ®Google Scholar
• . Bhasin S, Cunningham GR, Hayes FJ, . Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010
   PubMed Web of Science ®Google Scholar
• . Gliklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User's Guide. 2nd ed. (Prepared by Outcome DEcIDE Center [Outcome Sciences Inc. d/b/a/Outcome] under Contract No. HHSA29020050035I T03.) AHRQ Publication No. 10-EHC049. Rockville, MD: Agency for Heathcare Research and Quality. September 2010. http://effectivehealthcare.ahrq.gov/repFiles/PatOutcomes.pdf. Accessed February 12, 2013
   Google Scholar
• . Gliklich RE, Bertagna M. The emerging role of the patient registry. Good Clin Pract J. 2006;13(12):14–17
   Google Scholar
• . Miner MM, Khera M, Bhattacharya R, Blick G, Kushner H. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011;123(3):17–27
   PubMed Web of Science ®Google Scholar
• . Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186(3):1005–1011
   PubMed Web of Science ®Google Scholar
• . Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the US (TRiUS). J Sex Med. 2011;8(11):3204–3213
   PubMedGoogle Scholar
• . Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord. 2011;11(1):18
   PubMedGoogle Scholar
• . Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Martin MM. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012;15(1):14–21
   PubMed Web of Science ®Google Scholar
• . Blick G, Khera M, Bhattacharya RK, Nguyen D, Kushner H, Miner MM. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med. 2012;13(5):688–698
   PubMedGoogle Scholar
• . Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging. 2012;7:321–330
   PubMed Web of Science ®Google Scholar
• . O'Leary MP, Fowler FJ, Lenderking WR, . A brief male sexual function inventory for urology. Urology. 1995;46(5):697–706
   PubMed Web of Science ®Google Scholar
• . O'Leary MP, Rhodes T, Girman CJ, . Distribution of the Brief Male Sexual Inventory in community men. Int J Impot Res. 2003;15(3):185–191
   PubMed Web of Science ®Google Scholar
• . Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613
   PubMed Web of Science ®Google Scholar
• . Loizides E, Swierzewski MJ, O'Neill C, Griesser J, Smith T. Early response time in sexual activity and mood following testosterone gel replacement in hypogonadal males from the Testim® START study. Rev Urol. 2004;6( suppl 6):S16–S21
   Google Scholar
• . Seidman SN, Orr G, Raviv G, . Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. J Clin Psychopharmacol. 2009;29(3):216–221
   PubMed Web of Science ®Google Scholar
• . Seftel AD, Mack RJ, Secrest AR, Smith TM. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. JAndrol. 2004;25(6):963–972
   Google Scholar
• . Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88(6):2673–2681
   PubMed Web of Science ®Google Scholar
• . McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91(1):69–74
   PubMedGoogle Scholar
• . Wang C, Swerdloff RS, Iranmanesh A, . Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–2853
   PubMed Web of Science ®Google Scholar
• . Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of Testim(r) 1% testosterone gel in hypogonadal men. Rev Urol. 2005;7(2):87–94
   PubMedGoogle Scholar
• . Mykletun A Dahl AA O'Leary MP, Fossa SD. Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int. 2006;97(2):316–323
   PubMed Web of Science ®Google Scholar
• . Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care. 2004;42(12):1194–1201
   PubMed Web of Science ®Google Scholar
• . Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92(10):3844–3853
   PubMed Web of Science ®Google Scholar
• . Naharci MI, Pinar M, Bolu E, Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract. 2007;13(6):629–635
   PubMedGoogle Scholar
• . Simon D, Charles MA, Lahlou N, . Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care. 2001;24(12):2149–2151
   PubMed Web of Science ®Google Scholar
• . Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93(1):139–146
   PubMed Web of Science ®Google Scholar
• . Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1): 1–7
   PubMedGoogle Scholar
• . Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906
   PubMed Web of Science ®Google Scholar
• . Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. JAndol. 2009;30(6):726–733
   Google Scholar
• . Jones TH, Arver S, Behre HM, . Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care. 2011;34(4):828–837
   PubMed Web of Science ®Google Scholar
• . Jones TH. Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. J Diabetes. 2010;2(3):146–156
   PubMed Web of Science ®Google Scholar
• . Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren LJ. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685
   PubMed Web of Science ®Google Scholar
• . Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89(8):3813–3817
   PubMedGoogle Scholar
• . Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial? BJU Int. 2004;94(7):1066–1070
   PubMed Web of Science ®Google Scholar
• . Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–4343
   PubMed Web of Science ®Google Scholar